PANELIST
Margaret Doyle
Margaret joined Global Medical Affairs Janssen in September 2020 and is currently the Senior Global Medical
Affairs Leader for Teclistamab.
Margaret partners with internal colleagues and the external medical community to develop and support
teclistamab as a safe and effective treatment option for patients with Multiple Myeloma.
She also collaborates with experts in the field, leading their comprehensive publication strategy, executing
medical education plans and running pre-approval access programs.
Margaret joined Janssen Ireland in 2008 as an MSL, where she was responsible for the Hematology, Solid
Tumor and Immunology portfolio and moved into the Janssen EMEA regional organization in 2011, where she
supported the launch of Zytiga for metastatic castration resistant prostate cancer, Imbruvica for B Cell
Malignancies and our Myeloid portfolio.
Prior to joining Janssen, Margaret obtained a BSc Pharm degree at Trinity College, Dublin and her MSc in
Clinical Pharmacy at Queens University, Belfast. Margaret completed the Certificate of Competence in
Lymphoma through the University of Ulm in 2016 and completed Harvard Course in Immuno Oncology in 2021. She
spent her career prior to Janssen in oncology-based hospital pharmacy roles and in the community setting.